Analyzing the impact of different value-based insurance design programs

American Journal of Pharmacy Benefits

Volumn 4, Issue 1, 2012, Pages 29-36

  Barron, John J ^a   Cai, Qian ^a   Turner, Ralph M ^a   White, Jeff T ^b   Amirpoor, Laurie W ^c  

^a HEALTHCORE INC   (United States)

^b Wellpoint Inc   (United States)

^c Camarillo CA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COST CONTROL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84859790726     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635-2645.
2. Wagner TH, Heisler M, Piette JD. Prescription drug co-payments and cost-related medication underuse. Health Econ Policy Law. 2008;3(pt 1):51-67.
3. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-69.
4. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
5. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740.
6. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004; 42(7):626-634.
7. Lohr KN, Brook RH, Kamberg CJ, et al. Use of medical care in the Rand Health Insurance Experiment: diagnosis- and service-specific analyses in a randomized controlled trial. Med Care. 1986;24(suppl 9):S1-S87.
8. Wong MD, Andersen R, Sherbourne CD, Hays RD, Shapiro MF. Effects of cost sharing on care seeking and health status: results from the Medical Outcomes Study. Am J Public Health. 2001;91(11):1889-1894.
9. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
10. Blustein J. Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med. 1995;332(17):1138-1143.
11. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
12. Abraham JM, Deleire T, Royalty AB. Moral hazard matters: measuring relative rates of underinsurance using threshold measures. Health Serv Res. 2010;45(3): 806-824.
13. Chambers DW. Moral hazard. J Am Coll Dent. 2009;76(3):46-51.
14. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-867.
15. Spaulding A, Fendrick AM, Herman WH, et al. A controlled trial of value-based insurance design-the M Healthy: Focus on Diabetes (FOD) trial. Implement Sci. 2009;4:19.
16. Berger J. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. Am J Manag Care. 2007; 13(suppl 2):S55-S58.
17. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(suppl 5):S170-S176.
18. Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-536.
19. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917-932.
20. Diabetes Statistics. American Diabetes Association Web site. http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed September 28, 2010.
21. Rosenzweig JL, Taitel MS, Norman GK, Moore TJ, Turenne W, Tang P. Diabetes disease management in Medicare Advantage reduces hospitalizations and costs. Am J Manag Care. 2010;16(7):e157-e162.